Replies to post #80 on Iovance Biotherapeutics Inc (IOVA)

[jondoeuk]

Going forward they could drop Yervoy and expand the cells (ideally neoantigen-reactive) from biopsies [1]. Also, add other cytokines [2] plus an AKTi [3] ex vivo which should further improve efficacy. After the transfer of this improved product, use NKTR's bempeg (over IL-2) [4].

Refs:
1 https://journals.lww.com/immunotherapy-journal/Abstract/2018/11000/Utilizing_T_cell_Activation_Signals_1,_2,_and_3.2.aspx
2 https://link.springer.com/article/10.1007/s00262-012-1378-2
3 https://cancerres.aacrjournals.org/content/75/2/296.long
4 https://www.nature.com/articles/s41467-019-12901-3

[NY1972]

The target antigen was shedded in a hurry

Tumor regression was achieved in all patients (8-35% size decrease in target lesions) early after the T cell infusion with a median PFS of 86 days. At 12 weeks, 4 out of 6 patients had progressive disease (PD)